STRATA Skin Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 21, 2022

Rhea-AI Summary

STRATA Skin Sciences (NASDAQ: SSKN) announced it will release its fourth quarter and full year 2021 financial results on March 21, 2022, followed by a conference call at 4:30 p.m. ET. The call will review financial performance and provide corporate updates. STRATA focuses on developing innovative dermatological products, including excimer lasers and treatment systems for conditions like psoriasis and acne, targeting a significant patient base in the U.S.

Positive

• Plans to release financial results on March 21, 2022, indicating transparency with investors.
• Expansion into the estimated $5.5 billion U.S. acne care market through the acquisition of TheraClear system.

Negative

• None.

HORSHAM, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its fourth quarter and full year 2021 financial results on Monday, March 21, 2022. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the STRATA Skin Sciences website at: www.strataskinsciences.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial 1-877-451-6152 (US/Canada), 1-201-389-0879 (International), and use the conference ID number 13727130.

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions. Its products include the XTRAC®, XTRAC Momentum™ 1.0 and Pharos® excimer lasers, VTRAC® lamp systems, and TheraClear® treatment system utilized in the treatment of psoriasis, vitiligo, acne and various other skin conditions.

The Company’s proprietary XTRAC, XTRAC Momentum™ 1.0 and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents. Additionally, STRATA’s recently acquired assets related to Theravant Corporation’s TheraClear system allows the company the expand into the estimated $5.5 billion U.S. acne care market.

STRATA’s unique business model in the U.S. leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

Investor Contact
Jack Droogan
(203) 585-4140
ir@strataskin.com 

FAQ

When will STRATA Skin Sciences release its financial results?

STRATA Skin Sciences plans to release its fourth quarter and full year 2021 financial results on March 21, 2022.

What time is the STRATA Skin Sciences conference call?

The conference call is scheduled for 4:30 p.m. Eastern Time on March 21, 2022.

What products does STRATA Skin Sciences offer?

STRATA Skin Sciences offers products such as XTRAC, XTRAC Momentum 1.0, Pharos lasers, and TheraClear treatment systems.

What market is STRATA Skin Sciences expanding into?

STRATA Skin Sciences is expanding into the estimated $5.5 billion U.S. acne care market.